// App-Quantinova.ai

4183 : Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia

Researchers

Presenter

  • Paolo Strati

Principal Investigators

  • Michael Keating

  • Christina Hinojosa

  • Stefan Faderl

  • Susan C. Smith

  • Susan -Brien

  • Jan A. Burger

  • William G. Wierda

  • Alessandra Ferrajoli

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Metastatic pancreatic adenocarcinoma

  • Deep vein thrombosis

  • Pancreatic cancer

  • Venous thrombosis

  • Neutropenia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved